COMP <GO>
TXG vs AVTR // ALTMAN Z-SCORE & DEBT/EQUITY
10x Genomics Inc. (NASDAQ) VS. Avantor Inc. (NYSE) • 15-METRIC TALLY: TXG 7
— AVTR 5
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TXG
LAST: $61.63 (-12.09%) • MKT CAP: $9.13B
balance-sheet
25.02
LAST: $15.61 (-2.74%) • MKT CAP: $10.88B
balance-sheet
1.88
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TXG VS. AVTR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TXG | AVTR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 32.70% | +36.40 | TXG | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -5.70% | -2.10% | -3.60 | AVTR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.22% | 4.38% | -3.16 | AVTR | /fcf-yield <GO> |
| Operating Margin | -9.50% | -3.80% | -5.70 | AVTR | /operating-margins <GO> |
| Net Profit Margin | -6.80% | -8.10% | +1.30 | TXG | /net-margins <GO> |
| Revenue Growth (YoY) | 5.20% | -3.40% | +8.60 | TXG | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 25.02 | 1.88 | +23.14 | TXG | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 5/9 | +3.00 | TXG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.1 | 48.3 | -3.20 | AVTR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.01 | +0.14 | TXG | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 31.0x | -7.00 | TXG | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.13B | $10.88B | -$1.74B | AVTR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TXG REV | AVTR REV | TXG GROSS % | AVTR GROSS % | TXG FCF | AVTR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $642.8M | $6.55B | 69.1% | 32.7% | $130.1M | $495.0M |
| FY 2024 | $610.8M | $6.78B | 67.9% | 33.6% | -$5.7M | $692.0M |
| FY 2023 | $618.7M | $6.97B | — | — | -$43.0M | $556.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TXG // BETA 1.15
AVTR // BETA 1.01